Ostealtx
1 known investors
Find your way into Ostealtx
195 people in our graph share verified history with the Ostealtx team — schools, employers, funds. One of them is your warm intro.
Drew Burdonunlockedknows David Thompson · together at Smith+Nephew (overlapped)
×3knows the team · via Johnson & Johnson
knows the team · via UCSF Rosenman Institute
×6knows the team · via University of California, Berkeley, Haas School of Business
knows the team · via Smith+Nephew
Osteal Therapeutics is a clinical-stage pharmaceutical company developing novel treatments for orthopedic infections, particularly periprosthetic joint infections. Its lead product, NEXCHANGE KIT, is a drug-device combination designed for localized antibiotic delivery to infected joint prostheses.
Founders & leadership
BD
Brian de Beaubien, MDCo-Founder & Chief Medical Officer
DT
David ThompsoninChairman & CEODavid Thompson is a healthcare business leader with over 25 years of experience in medical devices, digital health, and diagnostics across organizations of varying sizes. He has led product development, commercial strategy, and go-to-market execution in areas including orthopedics, rare disease therapeutics, and combination products.
Investors · 1
Frequently asked questions
- What does Ostealtx do?
- Osteal Therapeutics is a clinical-stage pharmaceutical company developing novel treatments for orthopedic infections, particularly periprosthetic joint infections. Its lead product, NEXCHANGE KIT, is a drug-device combination designed for localized antibiotic delivery to infected joint prostheses.
- Who founded Ostealtx?
- Ostealtx was founded by Brian de Beaubien, MD.
- Who are Ostealtx's investors?
- Ostealtx's investors include HM Venture Partners.